Up to 80% of people’s health outcomes are influenced by non-clinical factors, however, most life sciences organizations lack a way of quantifying and understanding how they impact patient outcomes. Join industry leaders for a webinar to learn more about resources to help life sciences organizations better understand risk exposure for the communities and patients they serve.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Event Overview:
Up to 80% of people’s health outcomes are influenced by non-clinical factors such as economic
strain, food insecurity, health literacy, transportation barriers. These non-clinical factors can
dramatically impact areas like disease and treatment awareness, medication adherence, clinical
trial recruitment and more. Most life sciences organizations lack a way of quantifying and
understanding the wide array of factors beyond clinical care impacting patient outcomes.
Traditional social determinants of health (SDOH) data points alone do not provide the insights to
develop a clear, actionable patient profile to achieve equitable care.
Join industry leaders for a webinar to:
Key Learning Objectives:
- Discuss resources that can help your organization better understand risk exposure for the communities and patients you serve.
- Avoid strategies that systematically miss the most vulnerable communities, cohorts and patients.
- Leverage data to inform action across different therapeutic areas such as oncology and diabetes.
Who Should Attend:
Life Sciences Companies
Titles: Market Access, Payer Strategy, Access Strategy, Market Insights, Reimbursement, RWE, brand marketing, brand development, brand strategy, brand product marketing, commercialization, marketing and communications, analytics, health equity, HEOR
Speakers
Trenor Williams, MD
Co-founder and CEO
Socially Determined
Dr. Trenor Williams is a family physician, entrepreneur, former health system executive and consulting leader, past founder and CEO of Clinovations which he sold to the Advisory Board Company in 2014, and current CEO and CO-founder of Socially Determined. In 2017, Dr. Williams co-founded Socially Determined in order to create an analytics platform that integrates the social determinants of health with clinical and claims data in order to quantify and visualize social risk and the specific impacts on health and healthcare outcomes. With more than 20 years of healthcare experience, Dr. Williams’ unique perspective is formed at the intersection of healthcare and technology. He has an extensive understanding and knowledge in the implementation of healthcare technology, health plan market growth and SDOH strategy development for leading healthcare stakeholders here in the United States and around the world.
Mikki Nasch
Co-founder
Evidation Health
Mikki Nasch is focused on working to improve the patient experience. She is the former co-founder and head of business development at Evidation Health. Prior to Evidation, Mikki co-founded and led business activities at The Activity Exchange. Previously, Mikki was on the founding team of Sense Networks (exited to YP.com) and served as EVP of Business Development. Mikki has been the Vice President of Market Management at FairIsaac, Inc. (NYSE: FIC), held leadership positions in the incubation phase of numerous startups, and led development of products, sales strategies, business models and corporate vision, leading early-stage software venture capital funds. She was a founding member of BackWeb Technologies (NASD: BWEB), and began her career as a network engineer for the US and European governments.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Social Determinants of Health Data Evolution: Improve Access, Adherence and Achieve More Equitable Outcomes
Webcasts
Webinar Date/Time: Tue, May 16, 2023 2:00 PM EDT
Up to 80% of people’s health outcomes are influenced by non-clinical factors, however, most life sciences organizations lack a way of quantifying and understanding how they impact patient outcomes. Join industry leaders for a webinar to learn more about resources to help life sciences organizations better understand risk exposure for the communities and patients they serve.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Event Overview:
Up to 80% of people’s health outcomes are influenced by non-clinical factors such as economic
strain, food insecurity, health literacy, transportation barriers. These non-clinical factors can
dramatically impact areas like disease and treatment awareness, medication adherence, clinical
trial recruitment and more. Most life sciences organizations lack a way of quantifying and
understanding the wide array of factors beyond clinical care impacting patient outcomes.
Traditional social determinants of health (SDOH) data points alone do not provide the insights to
develop a clear, actionable patient profile to achieve equitable care.
Join industry leaders for a webinar to:
Key Learning Objectives:
Who Should Attend:
Life Sciences Companies
Titles: Market Access, Payer Strategy, Access Strategy, Market Insights, Reimbursement, RWE, brand marketing, brand development, brand strategy, brand product marketing, commercialization, marketing and communications, analytics, health equity, HEOR
Speakers
Trenor Williams, MD
Co-founder and CEO
Socially Determined
Dr. Trenor Williams is a family physician, entrepreneur, former health system executive and consulting leader, past founder and CEO of Clinovations which he sold to the Advisory Board Company in 2014, and current CEO and CO-founder of Socially Determined. In 2017, Dr. Williams co-founded Socially Determined in order to create an analytics platform that integrates the social determinants of health with clinical and claims data in order to quantify and visualize social risk and the specific impacts on health and healthcare outcomes. With more than 20 years of healthcare experience, Dr. Williams’ unique perspective is formed at the intersection of healthcare and technology. He has an extensive understanding and knowledge in the implementation of healthcare technology, health plan market growth and SDOH strategy development for leading healthcare stakeholders here in the United States and around the world.
Mikki Nasch
Co-founder
Evidation Health
Mikki Nasch is focused on working to improve the patient experience. She is the former co-founder and head of business development at Evidation Health. Prior to Evidation, Mikki co-founded and led business activities at The Activity Exchange. Previously, Mikki was on the founding team of Sense Networks (exited to YP.com) and served as EVP of Business Development. Mikki has been the Vice President of Market Management at FairIsaac, Inc. (NYSE: FIC), held leadership positions in the incubation phase of numerous startups, and led development of products, sales strategies, business models and corporate vision, leading early-stage software venture capital funds. She was a founding member of BackWeb Technologies (NASD: BWEB), and began her career as a network engineer for the US and European governments.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Delivery and Disruption: Navigating a Changing Care Terrain
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
A Risk-Reward Reset: Getting Serious About Social Media
As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Copay Adjustment Chess Match: What Will Payers Do Next?
As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Rx Power Struggle: How Pharma can Flip the PBM Script
The industry holds the key to true change to the drug access landscape.
Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031
A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.
Lilly Introduces Single-Dose Vials of Zepbound, Expanding Access for Adults with Obesity
The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.
Delivery and Disruption: Navigating a Changing Care Terrain
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
A Risk-Reward Reset: Getting Serious About Social Media
As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Copay Adjustment Chess Match: What Will Payers Do Next?
As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Rx Power Struggle: How Pharma can Flip the PBM Script
The industry holds the key to true change to the drug access landscape.
Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031
A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.
Lilly Introduces Single-Dose Vials of Zepbound, Expanding Access for Adults with Obesity
The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.